Alcoholic Hepatitis Treatment Market Report 2026

The alcoholic hepatitis treatment market size has grown strongly in recent years. It will grow from $3.43 billion in 2025 to $3.72 billion in 2026 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to increasing prevalence of alcoholic liver disease, growing awareness about alcohol-related health issues, adoption of corticosteroids and other drug therapies, expansion of hospital-based treatment programs, limited availability of stem cell therapies.

The alcoholic hepatitis treatment market size is expected to see strong growth in the next few years. It will grow to $5.26 billion in 2030 at a compound annual growth rate (CAGR) of 9.1%. The growth in the forecast period can be attributed to advancement in regenerative medicine and stem cell therapies, growing investment in private treatment centers, rising adoption of personalized medicine approaches, increasing government initiatives for liver disease management, development of novel biologics for liver protection. Major trends in the forecast period include rising adoption of corticosteroid and hemorheologic therapies, increasing use of stem cell therapy for liver regeneration, expansion of private treatment centers and clinics, growing focus on personalized treatment plans for alcoholic hepatitis, enhanced awareness and early diagnosis programs.

The increasing prevalence of liver diseases caused by alcohol consumption is expected to drive the growth of the alcoholic hepatitis treatment market in the coming years. Alcoholic liver disease occurs when the liver’s function is impaired. The liver performs numerous vital processes, such as cleansing the blood and producing bile to aid digestion. Alcoholic hepatitis treatment is used to manage liver inflammation in affected patients, and severe cases may require hospitalization for therapy. For instance, in April 2024, data published by the Office for Health Improvement and Disparities, a UK-based government agency, reported that premature deaths from liver disease in 2022 totaled 10,593, with 6,664 among males and 3,929 among females. In the financial year ending 2023, there were 85,665 hospital admissions for liver disease in England, equating to a rate of 155.2 per 100,000 population, including 27,085 admissions specifically for alcoholic liver disease, corresponding to a rate of 49.4 per 100,000 population. Therefore, the increasing prevalence of liver diseases caused by alcohol is fueling growth in the alcoholic hepatitis treatment market.

Major companies operating in the alcoholic hepatitis treatment market are focusing on product development, such as immunoassays, to drive revenue in the market. Immunoassays are biochemical tests that use the specific binding of antibodies to antigens to detect and measure the presence or concentration of a target molecule (analyte) in a sample. For instance, in November 2023, F. Hoffmann-La Roche Ltd., a Switzerland-based healthcare company, launched Elecsys HBeAg quant. This immunoassay measures the amount of hepatitis B e antigen (HBeAg) in human serum and plasma, both qualitatively and quantitatively. It can serve as a predictor of chronic active hepatitis and as an early indicator of acute hepatitis B infection. The test aids in the diagnosis and follow-up of individuals with hepatitis B virus infection when combined with other laboratory findings and clinical data. Elecsys HBeAg quant can be used on Roche's Cobas e analyzers and is suitable for samples from patients who have previously tested positive or whose HBeAg status is unknown.

In September 2025, Bausch Health Companies Inc., a Canada-based provider of pharmaceuticals, medical devices, and diversified healthcare products, acquired DURECT Corporation for approximately $63 million. Through this acquisition, Bausch Health aims to strengthen and expand its late-stage hepatology portfolio by adding larsucosterol, a Breakthrough Therapy-designated drug candidate for alcohol-associated hepatitis, to advance treatment options in an area with significant unmet medical need. DURECT Corporation is a US-based biopharmaceutical company that develops epigenetic and inflammation-targeted therapeutics, including its lead candidate larsucosterol for severe alcohol-associated hepatitis.

Major companies operating in the alcoholic hepatitis treatment market are Mallinckrodt Pharmaceuticals, Intercept Pharmaceuticals Inc., DURECT Corporation, BioVie Inc., Conatus Pharmaceuticals Inc., AbbVie Inc., Gilead Sciences Inc., Pfizer Inc., Merck And Co Inc., Bristol Myers Squibb Company, Johnson And Johnson, Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Limited, Bayer AG, Boehringer Ingelheim International GmbH, Madrigal Pharmaceuticals Inc., Genfit SA, CymaBay Therapeutics Inc., Zydus Cadila, Dr Reddys Laboratories Ltd.

North America was the largest region in the alcoholic hepatitis treatment market in 2025. It is expected to be the fastest-growing region in the forecast period. The regions covered in the alcoholic hepatitis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the alcoholic hepatitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the alcoholic hepatitis treatment market by increasing costs for imported drugs, biologics, and stem cell therapy materials. Drug segments such as corticosteroids, monoclonal antibodies, and other immunosuppressants are most affected, with regions in north america, europe, and asia-pacific experiencing higher procurement costs. This has led to increased treatment expenses and supply chain adjustments. On the positive side, tariffs have encouraged local manufacturing of therapeutics and fostered regional innovation in liver disease treatments.

The alcoholic hepatitis treatment market research report is one of a series of new reports that provides alcoholic hepatitis treatment market statistics, including alcoholic hepatitis treatment industry global market size, regional shares, competitors with a alcoholic hepatitis treatment market share, detailed alcoholic hepatitis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the alcoholic hepatitis treatment industry. This alcoholic hepatitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Alcoholic hepatitis treatment involves interventions aimed at promoting alcohol abstinence and managing the symptoms of liver damage. Treatment focuses on stopping alcohol consumption and providing therapies to reduce the signs and effects of liver injury.

The main types of treatment for alcoholic hepatitis include drug therapy and stem cell therapy. Drug therapy refers to the use of medications, apart from food, to prevent, detect, treat, or alleviate the symptoms of a disease or abnormal condition. Drug classes include corticosteroids, hemorheologic agents, monoclonal antibodies, anabolic steroids, and others, which are administered orally or by injection. These treatments are provided by hospitals, clinics, and private treatment centers.

The alcoholic hepatitis treatment market consists of revenues earned by entities by providing infection surveillance, ulcer prophylaxis, and liver transplantation. The market value includes the value of related goods sold by the service provider or included within the service offering. The alcoholic hepatitis treatment market also includes sales of anti-inflammatory medication such as steroids, pentoxifylline, and glucocorticoids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.